Skip to main content

Advertisement

Log in

Coexistence of chronic myeloid leukemia and pulmonary plasmacytoma mimicking primary lung cancer

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

A 61-year-old man was diagnosed with the simultaneous occurrence of chronic myeloid leukemia (CML) and infiltrative intrathoracic plasmacytoma, radiologically mimicking bronchogenic carcinoma. Following the administration of imatinib mesylate (IM; 400 mg/day), both hematologic and partial cytogenetic remission of CML were achieved. However, the pulmonary plasmacytoma was persistently aggravated. High-dose dexamethasone was added to the IM therapy because the patient refused radiotherapy to control the aggravated pulmonary plasmacytoma. Finally, he died due to pneumonia and multi-organ failure during concurrent administration of IM and high-dose dexamethasone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nitta M, Tsuboi K, Yamashita S, Kato M, Hayami Y, Harada S, et al. Multiple myeloma preceding the development of chronic myelogenous leukemia. Int J Hematol. 1999;69:170–3.

    CAS  PubMed  Google Scholar 

  2. Galanopoulos A, Papadhimitriou SI, Kritikou-Griva E, Georgiakaki M, Anagnostopoulos NI. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia. Ann Hematol. 2009;88:281–2.

    Article  CAS  PubMed  Google Scholar 

  3. Garipidou V, Vakalopoulou S, Tziomalos K. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate. Oncologist. 2005;10:457–8.

    Article  PubMed  Google Scholar 

  4. Michael M, Antoniades M, Lemesiou E, Papaminas N, Melanthiou F. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months. Oncologist. 2009;14:1198–200.

    Article  PubMed  Google Scholar 

  5. Schwarzmeier JD, Shehata M, Ackermann J, Hilgarth M, Kaufmann H, Drach J. Simultaneous occurrence of chronic myeloid leukemia and multiple myeloma: evaluation by FISH analysis and in vitro expansion of bone marrow cells. Leukemia. 2003;17:1426–8.

    Article  CAS  PubMed  Google Scholar 

  6. Klenn PJ, Hyun BH, Lee YH, Zheng WY. Multiple myeloma and chronic myelogenous leukemia-a case report with literature review. Yonsei Med J. 1993;34:293–300.

    CAS  PubMed  Google Scholar 

  7. Boots MA, Pegrum GD. Simultaneous presentation of chronic granulocytic leukaemia and multiple myeloma. J Clin Pathol. 1982;35:364–5.

    Article  CAS  PubMed  Google Scholar 

  8. Derghazarian C, Whittemore NB. Multiple myeloma superimposed on chronic myelocytic leukemia. Can Med Assoc J. 1974;110:1047–50.

    CAS  PubMed  Google Scholar 

  9. Ide M, Kuwahara N, Matsuishi E, Kimura S, Gondo H. Uncommon case of chronic myeloid leukemia with multiple myeloma. Int J Hematol. 2010;91:699–704.

    Article  PubMed  Google Scholar 

  10. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutierrez N, San Miguel JF. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol. 2003;123:858–68.

    Article  CAS  PubMed  Google Scholar 

  11. Tzilves D, Gatopoulou A, Zervas K, Katodritou E, Patakiouta F, Tarpagos A, Katsos I. Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report. World J Gastroenterol. 2007;13:2011–3.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gyeong-Won Lee.

About this article

Cite this article

Kim, H.J., Kim, M.J., Lee, M.J. et al. Coexistence of chronic myeloid leukemia and pulmonary plasmacytoma mimicking primary lung cancer. Int J Hematol 92, 651–654 (2010). https://doi.org/10.1007/s12185-010-0705-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0705-7

Keywords

Navigation